Skip to main content

26.10.2016 | Hepatitis B (JK Lim, Section Editor) | Ausgabe 4/2016

Current Hepatology Reports 4/2016

Future Therapy for Hepatitis B Virus and Hepatitis D Virus

Current Hepatology Reports > Ausgabe 4/2016
Cihan Yurdaydin, Ramazan Idilman
Wichtige Hinweise
This article is part of the Topical Collection on Hepatitis B


Chronic delta hepatitis (CDH) represents the least encountered but the most severe form of chronic viral hepatitis. Whereas in other forms of chronic viral hepatitis breakthrough advances has occurred in the last two decades, this did not happen in CDH. The only effective treatment in CDH consists of the use of pegylated interferons. Interferon therapy has to be given at high doses, and the optimal duration is unknown although there is data to suggest that treatment has to be individualized and prolonged treatment duration beyond 1 year is necessary. Effective treatment of chronic hepatitis B (CHB) could be of value in CDH as long as it significantly decreases hepatitis B surface antigen (HBsAg) levels. However, nucleos(t)ide analogs currently in use for the treatment of CHB do not affect HBsAg levels and are not beneficial in CDH. New treatment approaches for CHB aiming for functional or complete cure in CHB are attractive but most are in the preclinical stage of drug development and are not expected to be in use in the very near future. Hence, treatment development targeting different steps of the hepatitis delta virus is rationale. These include hepatocyte entry inhibitors, nucleic acid polymers, and prenylation inhibitors. The former two approaches may also be considered for CHB mono-infection. Studies on these three approaches have reached phase 2 studies in humans. The use of the hepatocyte entry inhibitor myrcludex B, several nucleic acid polymers, and the prenylation inhibitor lonafarnib in clinical trials have displayed some promising results and further data need to be generated but there is now, after decades of silence in terms of translational activity, for the first time a hope for effective new treatments in CDH.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf

Weitere Produktempfehlungen anzeigen
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2016

Current Hepatology Reports 4/2016 Zur Ausgabe

Hepatitis B (JK Lim, Section Editor)

The Cascade of Care in Chronic Hepatitis B

Hepatitis B (JK Lim, Section Editor)

Future Therapy for HBV: Role of Cell Cycle Inhibitors

Hepatitis C (J Ahn, Section Editor)

Hepatitis C and Hepatocellular Carcinoma

  1. Sie können e.Med Innere Medizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Sie können e.Med Allgemeinmedizin 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

Neu im Fachgebiet Innere Medizin

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin